Vigil is positioned as a specialized player in the high-value neurodegeneration space with two clinical candidates: VGL101 (iluzanebart) targeting rare ALSP and VG-3927 targeting Alzheimer's disease. The company has secured strategic backing from Sanofi and a commercial partnership with Amgen, validating its TREM2 platform approach.
Cyborg Score Rationale
Vigil demonstrates solid fundamentals with positive Phase 1 data, adequate cash runway into 2026, and validation from major pharma partnerships. However, as a clinical-stage company with significant losses ($84.3M in 2024) and pending acquisition by Sanofi, execution risk remains material.
Top Insights
Sanofi acquisition for up to $10/share ($600M total equity value) signals major pharma confidence in TREM2 platform but eliminates upside as independent company
VG-3927 Phase 1 data showed favorable safety with 50% sTREM2 reduction; Phase 2 planned Q3 2025 with potential for once-daily Alzheimer's therapy
Iluzanebart pursuing accelerated approval pathway for rare ALSP with Phase 2 final analysis expected Q2 2025
Cash position of $97.8M as of Dec 2024 provides runway through 2026; company is burning ~$90M annually in R&D and G&A
Named Competitors
Lecanemab (Leqembi) — Anti-amyloid monoclonal antibody for early Alzheimer's disease